$XLO
Xilio Therapeutics Inc

2022 Q3 Form 10-Q Financial Statement

#000155837022012756 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.168M $8.306M $6.304M
YoY Change 30.54% 57.85% 28.68%
% of Gross Profit
Research & Development $13.04M $16.25M $14.92M
YoY Change 24.53% -8.45% 28.39%
% of Gross Profit
Depreciation & Amortization $473.0K $445.0K $440.0K
YoY Change 23.82% 19.3% 25.71%
% of Gross Profit
Operating Expenses $20.21M $24.55M $21.22M
YoY Change 26.6% 6.72% 28.47%
Operating Profit -$20.21M -$24.55M -$21.22M
YoY Change 26.6% 6.72% 28.47%
Interest Expense -$200.0K -$100.0K -$200.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $416.0K -$61.00K -$129.0K
YoY Change -243.45% -64.94% -12.24%
Pretax Income -$19.79M -$24.61M -$21.35M
YoY Change 21.78% 6.18% 28.12%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$19.79M -$24.61M -$21.35M
YoY Change 21.78% 6.18% 28.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.72 -$0.90 -$0.78
Diluted Earnings Per Share -$0.72 -$0.90 -$0.78
COMMON SHARES
Basic Shares Outstanding 27.47M 27.38M 27.37M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $139.1M $159.4M $177.0M
YoY Change 39.47% 32.51% 25.31%
Cash & Equivalents $139.1M $159.4M $177.0M
Short-Term Investments
Other Short-Term Assets $3.171M $3.597M $4.128M
YoY Change -6.65% -16.1% 194.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $142.3M $163.0M $181.1M
YoY Change 34.8% 30.84% 26.97%
LONG-TERM ASSETS
Property, Plant & Equipment $7.553M $7.442M $7.468M
YoY Change 6.26% -44.67% -45.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $301.0K $335.0K $359.0K
YoY Change -29.51% -83.16% -82.25%
Total Long-Term Assets $15.10M $15.12M $15.27M
YoY Change -0.35% -2.06% -2.91%
TOTAL ASSETS
Total Short-Term Assets $142.3M $163.0M $181.1M
Total Long-Term Assets $15.10M $15.12M $15.27M
Total Assets $157.4M $178.1M $196.4M
YoY Change 30.39% 27.21% 24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.810M $1.410M $2.324M
YoY Change -52.64% -83.23% -10.89%
Accrued Expenses $9.062M $12.09M $7.323M
YoY Change 10.59% 37.13% -28.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $3.333M $1.667M
YoY Change -16.68% -49.98%
Total Short-Term Liabilities $16.84M $17.77M $12.23M
YoY Change 30.85% -16.59% -24.97%
LONG-TERM LIABILITIES
Long-Term Debt $4.781M $6.394M $8.012M
YoY Change -50.09% 16.66% 24.26%
Other Long-Term Liabilities $64.00K $82.00K $100.0K
YoY Change -95.8% -99.3% -99.16%
Total Long-Term Liabilities $64.00K $82.00K $100.0K
YoY Change -95.8% -99.52% -99.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.84M $17.77M $12.23M
Total Long-Term Liabilities $64.00K $82.00K $100.0K
Total Liabilities $31.12M $33.91M $30.23M
YoY Change -9.26% -11.8% -12.6%
SHAREHOLDERS EQUITY
Retained Earnings -$226.6M -$206.9M -$182.2M
YoY Change 60.53%
Common Stock $3.000K $3.000K $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.3M $144.2M $166.1M
YoY Change
Total Liabilities & Shareholders Equity $157.4M $178.1M $196.4M
YoY Change 30.39% 27.21% 24.0%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$19.79M -$24.61M -$21.35M
YoY Change 21.78% 6.18% 28.12%
Depreciation, Depletion And Amortization $473.0K $445.0K $440.0K
YoY Change 23.82% 19.3% 25.71%
Cash From Operating Activities -$19.91M -$16.76M -$20.84M
YoY Change -3.91% -16.79% -8.35%
INVESTING ACTIVITIES
Capital Expenditures -$333.0K -$771.0K $254.0K
YoY Change 192.11% 76.03% 49.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$333.0K -$771.0K -$254.0K
YoY Change 192.11% 76.03% 49.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -22.00K -21.00K -5.000K
YoY Change -107.31% -93.98% -100.0%
NET CHANGE
Cash From Operating Activities -19.91M -16.76M -20.84M
Cash From Investing Activities -333.0K -771.0K -254.0K
Cash From Financing Activities -22.00K -21.00K -5.000K
Net Change In Cash -20.26M -17.55M -21.09M
YoY Change -1.31% -16.13% -117.29%
FREE CASH FLOW
Cash From Operating Activities -$19.91M -$16.76M -$20.84M
Capital Expenditures -$333.0K -$771.0K $254.0K
Free Cash Flow -$19.58M -$15.99M -$21.09M
YoY Change -4.99% -18.85% -7.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Local Phone Number
LocalPhoneNumber
524-2466
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24613000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23181000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45966000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39848000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-31.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-55.16
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27384614
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
736473
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27376043
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
722424
dei Entity Central Index Key
EntityCentralIndexKey
0001840233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 xlo Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2021Q2 xlo Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1053
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40925
dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
857
dei Trading Symbol
TradingSymbol
XLO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27471607
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159410000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198053000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3597000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4464000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
163007000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
202517000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1554000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7442000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5789000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5977000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
335000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000
CY2022Q2 us-gaap Assets
Assets
178127000
CY2021Q4 us-gaap Assets
Assets
218060000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1410000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3144000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12087000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
858000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3333000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17770000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12778000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
6394000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9628000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9664000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10107000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
82000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000
CY2022Q2 us-gaap Liabilities
Liabilities
33910000
CY2021Q4 us-gaap Liabilities
Liabilities
32631000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27471607
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27391834
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27468950
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27358375
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
351066000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346312000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206852000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160886000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
144217000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
178127000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218060000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16246000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17745000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31166000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29366000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8306000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5262000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14610000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10161000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24552000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
23007000
us-gaap Operating Expenses
OperatingExpenses
45776000
us-gaap Operating Expenses
OperatingExpenses
39527000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24552000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23007000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45776000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39527000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-174000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-321000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-61000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-174000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-190000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-321000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24613000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23181000
us-gaap Net Income Loss
NetIncomeLoss
-45966000
us-gaap Net Income Loss
NetIncomeLoss
-39848000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-31.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-55.16
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27384614
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
736473
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27376043
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
722424
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
794000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16667000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-99135000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1002000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23181000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-121309000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2709000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24613000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
144217000
us-gaap Profit Loss
ProfitLoss
-45966000
us-gaap Profit Loss
ProfitLoss
-39848000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
885000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
723000
xlo Noncash Interest Expense
NoncashInterestExpense
106000
xlo Noncash Interest Expense
NoncashInterestExpense
78000
us-gaap Share Based Compensation
ShareBasedCompensation
4738000
us-gaap Share Based Compensation
ShareBasedCompensation
1796000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-19000
xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
44000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-857000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1398000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-188000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-159000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1217000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1921000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3204000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6159000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-386000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-205000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37591000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42870000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1025000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
608000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1025000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-608000
us-gaap Repayments Of Debt
RepaymentsOfDebt
333000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
144886000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144541000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38642000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
101063000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160964000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121852000
us-gaap Interest Paid Net
InterestPaidNet
240000
us-gaap Interest Paid Net
InterestPaidNet
253000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
154000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
xlo Deferred Offering Costs Included In Accounts Payable Or Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
1538000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159400000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
491000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Factors that may affect estimates include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to accrued expenses, the valuation of equity-based compensation, including stock options and restricted common stock, the useful life of long-lived assets and income taxes. Actual results could differ from those estimates.</p>
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8378472
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159410000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120299000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1554000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160964000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121852000
CY2022Q2 xlo Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2021Q2 xlo Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12087000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10972000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10332000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3530000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2712000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7442000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620000
us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
700000
CY2022Q2 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
8198000
CY2021Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
2794000
CY2022Q2 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
2991000
CY2021Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5145000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
593000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6732993
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2022Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2022Q2 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
5181011
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
4088456
CY2022Q2 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
2628110
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
2349875
CY2022Q2 xlo Common Stock Capital Shares Reserved For Future Issuance Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
566720
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
292031
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2709000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1002000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4738000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1796000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4088456
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30291000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1362816
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.35
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2657
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
267604
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.04
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5181011
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M8D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
87000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1366453
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5181011
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y11M8D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
87000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.71
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5263415
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21844379

Files In Submission

Name View Source Status
0001558370-22-012756-index-headers.html Edgar Link pending
0001558370-22-012756-index.html Edgar Link pending
0001558370-22-012756.txt Edgar Link pending
0001558370-22-012756-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20220630.xsd Edgar Link pending
xlo-20220630x10q.htm Edgar Link pending
xlo-20220630xex31d1.htm Edgar Link pending
xlo-20220630xex31d2.htm Edgar Link pending
xlo-20220630xex32d1.htm Edgar Link pending
xlo-20220630x10q_htm.xml Edgar Link completed
xlo-20220630_pre.xml Edgar Link unprocessable
xlo-20220630_def.xml Edgar Link unprocessable
xlo-20220630_cal.xml Edgar Link unprocessable
xlo-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable